Abingworth LLP lessened its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 19.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,971,907 shares of the company’s stock after selling 472,902 shares during the period. Crispr Therapeutics accounts for approximately 24.3% of Abingworth LLP’s investment portfolio, making the stock its largest holding. Abingworth LLP owned about 4.81% of Crispr Therapeutics worth $35,139,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of CRSP. Allianz Asset Management GmbH purchased a new position in Crispr Therapeutics in the third quarter valued at about $2,384,000. Credit Suisse AG purchased a new position in Crispr Therapeutics in the first quarter valued at about $1,742,000. Adams Street Partners LLC purchased a new position in Crispr Therapeutics in the third quarter valued at about $1,019,000. Hershey Trust Co. purchased a new position in Crispr Therapeutics in the third quarter valued at about $768,000. Finally, JPMorgan Chase & Co. purchased a new position in Crispr Therapeutics in the third quarter valued at about $536,000. Institutional investors own 24.55% of the company’s stock.
CRSP has been the topic of a number of research analyst reports. Barclays restated a “buy” rating and set a $29.00 price target on shares of Crispr Therapeutics in a research note on Friday, September 8th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. SunTrust Banks restated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a research note on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $22.38.
Shares of Crispr Therapeutics AG (CRSP) opened at $18.52 on Wednesday. Crispr Therapeutics AG has a 52 week low of $11.63 and a 52 week high of $25.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The business had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. Crispr Therapeutics’s revenue was up 54.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.77) EPS. sell-side analysts anticipate that Crispr Therapeutics AG will post -2.46 EPS for the current year.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.